Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
240 hedge funds and large institutions have $4.15B invested in Blueprint Medicines in 2022 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 70 increasing their positions, 89 reducing their positions, and 36 closing their positions.
72% more call options, than puts
Call options by funds: $24.4M | Put options by funds: $14.2M
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
30% more capital invested
Capital invested by funds: $3.19B → $4.15B (+$959M)
14% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 36
1% more funds holding
Funds holding: 237 → 240 (+3)
0.52% less ownership
Funds ownership: 106.02% → 105.5% (-0.52%)
21% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 89
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$85.1M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$35.9M |
| 3 |
CC
Casdin Capital
New York
|
+$35.3M |
| 4 |
BlackRock
New York
|
+$30.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$24.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$103M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$61.2M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$43.3M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$37.3M |
| 5 |
CCM
Cadian Capital Management
New York
|
-$36M |
BPMC Hedge Fund Activity: Q3 2022 in Review
240 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2022, worth a combined $4.15B — up 30% from $3.19B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new BPMC positions and 36 closed out — a net gain of 5 holders — while 70 added to existing stakes and 89 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $85.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $103M.
- 240 institutional investors held Blueprint Medicines (BPMC) as of Q3 2022, up from 237 in Q2 2022.
- Funds reported $4.15B of Blueprint Medicines stock for Q3 2022, up 30% quarter-over-quarter.
- 41 funds opened new Blueprint Medicines positions in Q3 2022 and 36 closed out, a net change of +5 holders.
- The largest Blueprint Medicines buyer in Q3 2022 was Wellington Management Group, an estimated $85.1M added.
- The largest Blueprint Medicines seller in Q3 2022 was T. Rowe Price Associates, an estimated $103M sold.
Based on aggregated 13F filings for Q3 2022.